Metformin May Reverse Hormone-Drug Resistance in Prostate Cancer, Lab Study Finds
Prostate tumors dodge a cell-death pathway using the GSTA4 protein; metformin blocked it and re-sensitized tumors to hormone-blocking drugs in cell and animal models.
By Sanare Lab · September 28, 2026 · 2 min read
Key Takeaway
Prostate cancers often stop responding to hormone-blocking (antiandrogen) drugs. A new study shows one reason: a protective protein called GSTA4 shields tumor cells from ferroptosis, an iron-driven form of cell death. The diabetes drug metformin blocked GSTA4 and restored the drugs' effect in cell and animal models — this is preclinical (lab-stage) research.
The study focused on castration-resistant prostate cancer — tumors that keep growing even when hormone therapy is working. GSTA4 turned out to defend the tumor on two fronts: in the cell's main compartment it neutralizes 4-HNE (a toxic substance released when fats burn), and under stress it slips into mitochondria (the cell's power plants) and, through the PGAM5/Drp1 switch, keeps them healthy. Patients with more GSTA4 had worse outcomes.
To find a blocker, the team ran a virtual screen of drug libraries and confirmed the hit with surface plasmon resonance (a precise lab test for whether two molecules bind). Metformin bound GSTA4 directly. In cell cultures and in mice, metformin treatment restored ferroptosis and made resistant tumors respond to antiandrogen therapy again.
Context: here metformin acts as a targeted enzyme blocker, not at a typical supplement dose, and no patients were treated — human trials are needed. For related reading, see the fenbendazole evidence in prostate cancer and the Care Oncology Protocol, which includes metformin; for dosing questions, our dosing calculator.
In plain words
What happened: Researchers tested metformin in prostate cancer cell and animal models to see whether it could restore sensitivity to hormone-blocking drugs.
Why it matters: A protein called GSTA4 may protect cancer cells from a type of cell damage. The study found metformin could block this protection in its models.
How strong is the evidence: This was preclinical research in cells and animals, not a trial in patients. It does not establish that metformin reverses treatment resistance in people.
What it means for you: Nothing changes in care today. Do not add metformin or change hormone treatment based on these findings; ask your oncologist.
References
- Luo Y, Zhuang W, Li Z, et al. Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer. Adv Sci (Weinh). 2026 Sep 27. doi:10.1002/advs.77908. PMID: 42801628.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The study was done in cell cultures and mice, not humans, and is not a clinical trial. Never start, stop or change any medication without consulting a licensed healthcare provider.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.